Loading…
Lobbying Spend
—
Filings
40
Firms Hired
2
Active Period
2010–2017
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
H.R. 9 (Innovation Act), all provisions relating to fee-shifting and inter partes review S. 1137 (PATENT Act), all provisions related to fee-shifting and inter partes review
Client expense: — · Firm income: $30,000
Matched citations: H.R. 9
H.R. 9 (Innovation Act), all provisions relating to fee-shifting and inter partes review S. 1137 (PATENT Act), all provisions related to fee-shifting and inter partes review
Client expense: — · Firm income: $30,000
Matched citations: S. 1137
Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015" language in - H.R.6 - 21st Century Cures Act.
Client expense: — · Firm income: $10,000
Matched citations: H.R.512
Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015" language in - H.R.6 - 21st Century Cures Act.
Client expense: — · Firm income: $10,000
Matched citations: H.R.6
H.R. 9 (Innovation Act), all provisions relating to fee-shifting and inter partes review S. 1137 (PATENT Act), all provisions related to fee-shifting and inter partes review
Client expense: — · Firm income: $30,000
Matched citations: H.R. 9
H.R. 9 (Innovation Act), all provisions relating to fee-shifting and inter partes review S. 1137 (PATENT Act), all provisions related to fee-shifting and inter partes review
Client expense: — · Firm income: $30,000
Matched citations: S. 1137
Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - "DISARM Act of 2015."
Client expense: — · Firm income: $10,000
Matched citations: H.R.512
H.R. 9 (Innovation Act), all provisions relating to fee shifting
Client expense: — · Firm income: $70,000
Matched citations: H.R. 9
Development of policies to advance the antimicrobial research and development environment. Support of H.R.4187 - "DISARM Act of 2014."
Client expense: — · Firm income: $7,500
Matched citations: H.R.4187
Prescription Drug Abuse Prevention and Treatment Act of 2013
2014 · fourth_quarter · Firm: ARENTFOX SCHIFF LLP
H.R. 672 (Prescription Drug Abuse Prevention and Treatment Act of 2013), all provisions Abuse deterrent formulations
Client expense: — · Firm income: $70,000
Matched citations: H.R. 672
Patent Abuse Reduction Act of 2013
2014 · fourth_quarter · Firm: ARENTFOX SCHIFF LLP
S. 1720 (Patent Transparency and Improvements Act of 2013), entire bill S. 1013 (Patent Abuse Reduction Act of 2013)(Section 5), all provisions relating to fee shifting
Client expense: — · Firm income: $70,000
Matched citations: S. 1013
Patent Transparency and Improvements Act of 2013
2014 · fourth_quarter · Firm: ARENTFOX SCHIFF LLP
S. 1720 (Patent Transparency and Improvements Act of 2013), entire bill S. 1013 (Patent Abuse Reduction Act of 2013)(Section 5), all provisions relating to fee shifting
Client expense: — · Firm income: $70,000
Matched citations: S. 1720
Prescription Drug Abuse Prevention and Treatment Act of 2013
2014 · third_quarter · Firm: ARENTFOX SCHIFF LLP
H.R. 672 (Prescription Drug Abuse Prevention and Treatment Act of 2013), all provisions Abuse deterrent formulations
Client expense: — · Firm income: $30,000
Matched citations: H.R. 672
Patent Abuse Reduction Act of 2013
2014 · third_quarter · Firm: ARENTFOX SCHIFF LLP
S. 1720 (Patent Transparency and Improvements Act of 2013), entire bill S. 1013 (Patent Abuse Reduction Act of 2013)(Section 5), all provisions relating to fee shifting
Client expense: — · Firm income: $30,000
Matched citations: S. 1013
Patent Transparency and Improvements Act of 2013
2014 · third_quarter · Firm: ARENTFOX SCHIFF LLP
S. 1720 (Patent Transparency and Improvements Act of 2013), entire bill S. 1013 (Patent Abuse Reduction Act of 2013)(Section 5), all provisions relating to fee shifting
Client expense: — · Firm income: $30,000
Matched citations: S. 1720
Development of policies to advance the antimicrobial research and development environment. Support of H.R.4187 - "DISARM Act of 2014."
Client expense: — · Firm income: $7,500
Matched citations: H.R.4187
Prescription Drug Abuse Prevention and Treatment Act of 2013
2014 · second_quarter · Firm: ARENTFOX SCHIFF LLP
H.R. 672 (Prescription Drug Abuse Prevention and Treatment Act of 2013), all provisions Abuse deterrent formulations
Client expense: — · Firm income: $80,000
Matched citations: H.R. 672
Patent Abuse Reduction Act of 2013
2014 · second_quarter · Firm: ARENTFOX SCHIFF LLP
S. 1720 (Patent Transparency and Improvements Act of 2013), entire bill S. 1013 (Patent Abuse Reduction Act of 2013)(Section 5), all provisions relating to fee shifting
Client expense: — · Firm income: $80,000
Matched citations: S. 1013
Patent Transparency and Improvements Act of 2013
2014 · second_quarter · Firm: ARENTFOX SCHIFF LLP
S. 1720 (Patent Transparency and Improvements Act of 2013), entire bill S. 1013 (Patent Abuse Reduction Act of 2013)(Section 5), all provisions relating to fee shifting
Client expense: — · Firm income: $80,000
Matched citations: S. 1720
Development of policies to advance the antimicrobial research and development environment. Support of H.R.4187 - "DISARM Act of 2014."
Client expense: — · Firm income: $7,500
Matched citations: H.R.4187
Development of policies to advance the antimicrobial research and development environment. Support of H.R.4187 - "DISARM Act of 2014."
Client expense: — · Firm income: $7,500
Matched citations: H.R.4187
Prescription Drug Abuse Prevention and Treatment Act of 2013
2014 · first_quarter · Firm: ARENTFOX SCHIFF LLP
H.R. 672 (Prescription Drug Abuse Prevention and Treatment Act of 2013), all provisions Abuse deterrent formulations
Client expense: — · Firm income: $120,000
Matched citations: H.R. 672
Patent Abuse Reduction Act of 2013
2014 · first_quarter · Firm: ARENTFOX SCHIFF LLP
S. 1720 (Patent Transparency and Improvements Act of 2013), entire bill S. 1013 (Patent Abuse Reduction Act of 2013)(Section 5), all provisions relating to fee shifting
Client expense: — · Firm income: $120,000
Matched citations: S. 1013
Patent Transparency and Improvements Act of 2013
2014 · first_quarter · Firm: ARENTFOX SCHIFF LLP
S. 1720 (Patent Transparency and Improvements Act of 2013), entire bill S. 1013 (Patent Abuse Reduction Act of 2013)(Section 5), all provisions relating to fee shifting
Client expense: — · Firm income: $120,000
Matched citations: S. 1720
Prescription Drug Abuse Prevention and Treatment Act of 2013
2013 · fourth_quarter · Firm: ARENTFOX SCHIFF LLP
H.R. 672 (Prescription Drug Abuse Prevention and Treatment Act of 2013), all provisions Abuse deterrent formulations
Client expense: — · Firm income: $60,000
Matched citations: H.R. 672
Source: Senate LDA